MGNX
MACROGENICS INC
NASDAQ · Healthcare · Biotechnology · US
$3.33
+2.46%Oct 15, 2026, 20:05 UTC
MacroGenics announced that the first patient was dosed in the Phase 1 study of MGC030 for advanced solid tumors.
Source:Aug 13, 2026, 20:05 UTC
MacroGenics, Inc. reported its financial results for the second quarter ended June 30, 2026, and highlighted recent corporate and pipeline progress.
Source:Aug 11, 2026, 20:05 UTC
Gilead Sciences exercised its option to exclusively license a preclinical bispecific program from MacroGenics under their 2022 collaboration agreement, triggering a $10 million payment to MacroGenics.
Source:Jul 2, 2026, 13:25 UTC
MacroGenics completed the sale of its GMP drug substance manufacturing operations to Bora Pharmaceuticals.
Source: